New drug with BCG for high-risk bladder cancer after BCG failure
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug (IAP0971) given with BCG, a standard bladder treatment, to see if it helps people with high-risk bladder cancer that hasn't spread into the muscle. You may join if you've already tried BCG and it didn't work, and you're not having your bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a type of bladder cancer that hasn't spread into the bladder muscle (called non-muscle invasive bladder cancer).
- You have already tried BCG treatment (a bladder instillation) and it didn't work or the cancer returned.
- You are not eligible for or have chosen not to have surgery to remove your bladder.
- You are in good general health, with normal organ function and an activity level of 0 or 1 on a standard scale.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.